Skip to main content

Breast Cancer

Breast Cancer

For Patients with PIK3CA Mutation–Positive Advanced Breast Cancer, Treatment with Alpelisib plus Fulvestrant May Be Beneficial

Breast Cancer

Perspectives on Balancing Toxicity and Efficacy When Managing Advanced HER2-Negative Breast Cancer with First-Line Treatment

Breast Cancer, CDK4/6 Inhibitors

Efficacy Study of Everolimus and Exemestane for the Treatment of Patients with Metastatic Hormone Receptor–Positive Breast Cancer Previously Treated with CDK4/6 Inhibitors

Breast Cancer, CDK4/6 Inhibitors, Radiation Therapy

Effect of Concomitant Treatment with Radiation Therapy and CDK4/6 in Patients with Advanced Breast Cancer

Breast Cancer, CDK4/6 Inhibitors

Recent Phase 2 Results for Lerociclib (G1T38), an Oral CDK4/6 Inhibitor Combined with Fulvestrant Used to Treat Patients with Advanced Breast Cancer

Breast Cancer

Management Strategies for Abemaciclib-Associated Diarrhea in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer

Benefit of Alpelisib When Combined with Fulvestrant as Demonstrated Through Biomarker Subanalysis from the SOLAR-1 Study

Breast Cancer

Overall Survival Benefit with Ribociclib plus Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: 4-Year Follow-Up Study of MONALEESA-7

Breast Cancer

BYLieve Study Results Support the Use of Alpelisib Combined with Fulvestrant for Hormone Receptor–Positive, HER2-Negative, PIK3CA Mutation–Positive Advanced Breast Cancer

Breast Cancer

PALOMA-3 Trial Shows Benefits to Overall Survival as Measured by Prognostic Indicators

5
6
7
8
9
10
11

Page 8 of 12
Results 71 - 80 of 114